Protara Therapeutics, Inc. Debt Instrument, Convertible, Conversion Ratio
Protara Therapeutics, Inc. (TARA) reported Debt Instrument, Convertible, Conversion Ratio of 19.08% for the 0-month period ending 2020-01-09, per its 10-K filed 2021-03-11.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionRatio1 · last filed 2021-03-11
- 2020-01-09: Debt Instrument, Convertible, Conversion Ratio 0 month 19.08%.
| Period end | Debt Instrument, Convertible, Conversion Ratio 0 month |
|---|---|
| 2020-01-09 | 19.08% 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |